Trending...
- Michael Judkins Releases New Poetry Book, Deeper Than You Think
- Chester County Tile Expert Reveals Top Home Value Mistakes Homeowners Make During Remodeling Projects
- Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
SAN DIEGO, June 17, 2024 ~ In a recent announcement, Primrose Bio, Inc. revealed that it has received a significant equity investment from 1315 Capital, a healthcare-focused growth equity firm based in Philadelphia. This investment will provide the necessary funds for the company to further develop and expand its three major offerings.
Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.
One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.
Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.
More on The PennZone
Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.
Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.
Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."
With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.
One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.
Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.
More on The PennZone
- HELM Audio™ Partners with PQCrypto to Future-Proof Children's Hearing and Safety Data Using Post-Quantum Cryptography
- Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4
- IDI Consulting Launches IDI AI, Enterprise-Level AI Services Built for Production, Scale, and ROI
- Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living
- Sleep Basil Launches Revamped Diamond Mattress Collection Page, Highlighting Performance, Craftsmanship, and Personalized Comfort
Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.
Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.
Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."
With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
Filed Under: Business
0 Comments
Latest on The PennZone
- TiNY Puts Real Pets on the Payroll for New PetArmor Campaign
- P‑Wave Classics Launches Definitive New Edition of Hannah Webster Foster's The Coquette
- Strategic Expansion with 3 New Alliances — Jefferson Beach Yacht Sales, CFR YS & flyExclusive Incentive Partnership: Off The Hook YS: (N Y S E: OTH)
- Super League (N A S D A Q: SLE) Advances AI-Driven Playable Media with AdArcade, Solsten, and Meta-Stadiums Partnerships, Plus Roblox Theatre Launch
- purelyIV Expands Concierge Wellness Platform with New IV Therapies, Memberships, and Digital Experience
- CCHR: Europe Rejects Forced Psychiatry—Landmark Vote Declares Coercive Practices Incompatible with Human Rights
- Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide
- OpenSSL Corporation Advisory Committees' Elections 2026: Voting Now Open
- Good Vibes Club and Instant IP Forge Strategic Partnership to Secure IP Brand Value in a Booming Digital Economy
- Inkdnylon Simplifies Digitizing and Vector Art Nationwide With Clear Pricing and Guided File Support
- goldsilbermarkt.de Awarded "Business Champion" in Online Retail by DISQ
- Daniel Guest of Imagen Golf Named to GRAA Top 100 Emerging Golf Professionals
- InspireTech Global and SKADI Cyber Defense Announce Strategic Partnership to Deliver Autonomous Cybersecurity to Canadian Education and Public Sector
- Kaltra Expands Microchannel Innovation to Deliver Lower Refrigerant Charge
- Georgia's Lanier Islands Resort Tees Up for a New Era of Golf in Spring 2026
- We Have Lots Of Loads LLC Expands Nationwide
- Eagle Americas Expands Into the Western U.S. With High West Machine Tool
- Desert Mountain Club Earns Prestigious Blue Zones Approved™ Triple Designation, a New Standard for Well-Being in a Luxury Lifestyle Community
- Outsports announces record-breaking number of LGBTQ+ athletes at 2026 Milan Winter Olympics
- Sheffield Clinic Highlights Safe, Inclusive Laser Hair Removal While Improving Access